Meloxicam has been reported to relieve oxidative stress by inhibiting NADPH oxidase (NOX1/NOX4) and simultaneously activating the Nrf2 pathway and upregulating the expression of downstream antioxidant enzymes, thereby exerting neuroprotective effects in experimental models of central nervous system diseases [19]. Here, FMO5 is linked to central nervous system disorder.